ClinicalTrialsFinder
RecruitingPhase 2NCT06994338

Tirzepatide for Alcohol Use Disorder

Phase II Evaluation of Tirzepatide in Adults With Alcohol Use Disorder and Overweight or Obesity

Sponsor

University of Southern California

Enrollment

42 participants

Start Date

Oct 6, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity and OverweightAlcohol Use DisorderAlcohol

Summary

The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.

Eligibility

Min Age: 21 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo injections and a drug called Tirzepatide for people with alcohol, alcohol use disorder, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTirzepatide

Tirzepatide injections (2.5mg, 5.0mg)

DRUGPlacebo injections

Placebo injections

Locations(1)

Keck School of Medicine, University of Southern California

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06994338

Related Trials

Hepatic Lipid Metabolism-Alcohol Use Disorder

NCT071915611 location

Environment and Alcohol: A Pilot Study

NCT068606071 location

Spironolactone in Alcohol Use Disorder (SAUD)

NCT058071391 location

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT060158931 location

Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP

NCT065527411 location